The International Association of Parkinsonism and Related Disorders world congress will be held in Lyon, France on 19-22 August. Dr. Stephen Shrewsbury, CMO will be presenting a poster on A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic (PK/PDyn) Study of INP103 (POD® L dopa) Administered in the...

Impel's Clinical Operations team will be attending the annual summer networking event of the Pacific Northwest Association of Clinical Research Professionals (ACRP). The event will be held Tuesday, August 7 at 5:30 - 7:30 PM at Chandler's Crabhouse on Lake Union.  For more information, visit the event webpage here....

Safety, Tolerability and Comparative Bioavailability of a Novel Intranasal DHE Product (INP104)   Abstract Migraine remains a serious cause of disability.1,2 Up to 42% of migraineurs still report dissatisfaction with their treatment,3 over a third (37%) with the speed of effect and half (50%) were dissatisfied that their pain recurred. Dihydroergotamine (DHE) is effective...

Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that Lynn C. Gold, Ph.D., has joined the Company as the Senior Vice President of Regulatory Affairs. In this capacity, Gold has extensive oversight of regulatory strategy, agency communication, and regulatory submissions. "We...

Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced new data from the Company’s investigational drug INP104 for acute migraine will be presented at the American Headache Society’s 60th Annual Meeting, June 28 – July 1, 2018. These data...

Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of INP104, a novel, dihydroergotamine (DHE) product dosed via...

The Impel team will be attending the 60th Annual American Headache Society meeting on June 28th - July 1 in San Francisco, CA. Our team will be made up of Jon Congleton, CEO; Steve Shrewsbury, CMO; Meghan Swardstrom, VP of Clinical Operations; Maria Jeleva, Associate Director of Clinical Operations; and Sutapa Ray, Business Development Manager....

Study to Explore the Therapeutic Benefit of Intranasal Levodopa in Parkinson’s Disease OFF Reversal (THOR 201) SEATTLE, May 31, 2018 -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of a Phase IIa study designed to explore...